What's new

Human medicines European public assessment report (EPAR): Yesafili, aflibercept, Date of authorisation: 15/09/2023, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Yesafili, aflibercept, Date of authorisation: 15/09/2023, Revision: 4, Status: Authorised

May 12, 2025 - 13:51
 0
Human medicines European public assessment report (EPAR): Yesafili, aflibercept, Date of authorisation: 15/09/2023, Revision: 4, Status: Authorised
Human medicines European public assessment report (EPAR): Yesafili, aflibercept, Date of authorisation: 15/09/2023, Revision: 4, Status: Authorised
Read More

Tags:

Previous Article

Human medicines European public assessment report (EPAR): Targretin, bexarotene,...

Next Article

Niche luxury fragrances brands face challenges in China

Related Posts

Human medicines European public assessment report (EPAR): Xyrem, sodium oxybate, Date of authorisation: 13/10/2005, Revision: 37, Status: Authorised

Human medicines European public assessment report (EPAR...

May 12, 2025  0

EMA workshop on primary efficacy endpoints for antivirals and mAbs intended for the treatment of COVID-19 and Influenza, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 5 June 2025, 13:00 (CEST) to 6 June 2025, 17:00 (CEST)

EMA workshop on primary efficacy endpoints for antivira...

May 12, 2025  0

Human medicines European public assessment report (EPAR): Jentadueto, linagliptin,metformin hydrochloride, Date of authorisation: 19/07/2012, Revision: 23, Status: Authorised

Human medicines European public assessment report (EPAR...

May 8, 2025  0